Last update 03 Apr 2025

BI-765049

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
BI 765049, BI-765049
Action
stimulants, inhibitors
Mechanism
CD3 stimulants(T cell surface glycoprotein CD3 stimulants), NCR3LG1 inhibitors(natural killer cell cytotoxicity receptor 3 ligand 1 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colonic CancerPhase 1
United States
28 Mar 2025
Colonic CancerPhase 1
Germany
28 Mar 2025
Colonic CancerPhase 1
Spain
28 Mar 2025
Pancreatic Ductal AdenocarcinomaPhase 1
United States
28 Mar 2025
Pancreatic Ductal AdenocarcinomaPhase 1
Germany
28 Mar 2025
Pancreatic Ductal AdenocarcinomaPhase 1
Spain
28 Mar 2025
Rectal CancerPhase 1
United States
28 Mar 2025
Rectal CancerPhase 1
Germany
28 Mar 2025
Rectal CancerPhase 1
Spain
28 Mar 2025
Stomach CancerPhase 1
United States
28 Mar 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free